Form 4: Amphastar Pharmaceuticals Executives Exercise Stock Options and Sell Shares to Cover Costs

Jack Y. Zhang and Mary Z. Luo, key executives at Amphastar Pharmaceuticals, exercised stock options and sold shares to cover exercise costs and tax liabilities.

Summary

• Jack Y. Zhang, CEO & Chief Scientific Officer, and Mary Z. Luo, COO, Chief Scientist, and Chairman at Amphastar Pharmaceuticals, engaged in transactions involving company stock.
• On March 14, 2025, Zhang exercised options to acquire 290,477 shares at $14.69 per share and sold 226,285 shares at $26.66 to cover the exercise price and withholding taxes.
• On the same day, Zhang exercised options to acquire 211,213 shares indirectly through Mary Z. Luo at $14.69 per share and sold 162,657 shares at $26.66 to cover the exercise price and withholding taxes.
• Additional sales of shares held directly and indirectly by Zhang occurred on March 15 and 17, 2025, to satisfy tax liabilities related to the vesting of restricted stock units (RSUs).
• Following these transactions, Zhang directly owns 2,647,659 shares and indirectly owns 1,185,475 shares through Mary Z. Luo, and 6,827,679 shares through Applied Physics and Chemistry Laboratories, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by company executives. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased number of shares in the market, but the impact is likely minimal given the relatively small volume of shares sold compared to the total outstanding shares.

Key Dates